Multivesicular bodies (MVBs) are endocytic compartments that enclose intraluminal vesicles (ILVs) formed by inward budding from the limiting membrane of endosomes. In T lymphocytes, these ILV contain Fas ligand (FasL) and are secreted as 'lethal exosomes' following activation-induced fusion of the MVB with the plasma membrane. Diacylglycerol (DAG) and diacylglycerol kinase α (DGKα) regulate MVB maturation and polarized traffic, as well as subsequent secretion of pro-apoptotic exosomes, but the molecular basis underlying these phenomena remains unclear. Here we identify protein kinase D (PKD) family members as DAG effectors involved in MVB genesis and secretion. We show that the inducible secretion of exosomes is enhanced when a constitutively active PKD1 mutant is expressed in T lymphocytes, whereas exosome secretion is impaired in PKD2-deficient mouse T lymphoblasts and in PKD1/3-null B cells. Analysis of PKD2-deficient T lymphoblasts showed the presence of large, immature MVB-like vesicles and demonstrated defects in cytotoxic activity and in activation-induced cell death. Using pharmacological and genetic tools, we show that DGKα regulates PKD1/2 subcellular localization and activation. Our studies demonstrate that PKD1/2 is a key regulator of MVB maturation and exosome secretion, and constitutes a mediator of the DGKα effect on MVB secretory traffic.
Multivesicular bodies (MVBs) are endocytic compartments that enclose intraluminal vesicles (ILVs) formed by inward budding from the limiting membrane of endosomes. In T lymphocytes, these ILV contain Fas ligand (FasL) and are secreted as 'lethal exosomes' following activation-induced fusion of the MVB with the plasma membrane. Diacylglycerol (DAG) and diacylglycerol kinase α (DGKα) regulate MVB maturation and polarized traffic, as well as subsequent secretion of pro-apoptotic exosomes, but the molecular basis underlying these phenomena remains unclear. Here we identify protein kinase D (PKD) family members as DAG effectors involved in MVB genesis and secretion. We show that the inducible secretion of exosomes is enhanced when a constitutively active PKD1 mutant is expressed in T lymphocytes, whereas exosome secretion is impaired in PKD2-deficient mouse T lymphoblasts and in PKD1/3-null B cells. Analysis of PKD2-deficient T lymphoblasts showed the presence of large, immature MVB-like vesicles and demonstrated defects in cytotoxic activity and in activation-induced cell death. Using pharmacological and genetic tools, we show that DGKα regulates PKD1/2 subcellular localization and activation. Our studies demonstrate that PKD1/2 is a key regulator of MVB maturation and exosome secretion, and constitutes a mediator of the DGKα effect on MVB secretory traffic. Exosomes are nanovesicles that form as intraluminal vesicles (ILVs) inside multivesicular bodies (MVBs) and are then secreted by numerous cell types. 1 ILVs are generated by inward budding of late endosome limiting membrane in a precisely regulated maturation process. 2, 3 Two main pathways are involved in MVB maturation. 4, 5 In addition to the ESCRT (endosomal complex required for traffic) proteins, 6 there is increasing evidence that lipids such as lyso-bisphosphatidic acid (LBPA), 7 ceramides 8 and diacylglycerol (DAG) 9 contribute to this membrane invagination process.
Exosomes participate in many biological processes related to T-cell receptor (TCR)-triggered immune responses, including T lymphocyte-mediated cytotoxicity and activationinduced cell death (AICD), antigen presentation and intercellular miRNA exchange. [10] [11] [12] [13] [14] [15] The discovery of exosome involvement in these responses increased interest in the regulation of exosome biogenesis and secretory traffic, with special attention to the contribution of lipids such as ceramide and DAG, as well as DAG-binding proteins. 14, [16] [17] [18] [19] [20] [21] These studies suggest that positive and negative DAG regulators may control secretory traffic. By transforming DAG into phosphatidic acid (PA), diacylglycerol kinase α (DGKα) is essential for the negative control of DAG function in T lymphocytes. 22 DGKα translocates transiently to the T-cell membrane after human muscarinic type 1 receptor (HM1R) triggering or to the immune synapse (IS) after TCR stimulation; at these subcellular locations, DGKα acts as a negative modulator of phospholipase C (PLC)-generated DAG. 23, 24 The secretory vesicle pathway involves several DAGcontrolled checkpoints at which DGKα may act; these include vesicle formation and fission at the trans-Golgi network (TGN), MVB maturation, as well as their transport, docking and fusion to the plasma membrane. 9, [16] [17] [18] [19] [20] The molecular components that regulate some of these trafficking processes include protein kinase D (PKD) family members. 21 PKD1 activity, for instance, regulates fission of transport vesicles from TGN via direct interaction with the pre-existing DAG pool at this site. 19 The cytosolic serine/threonine kinases PKD1, PKD2 and PKD3 (ref. 21) are expressed in a wide range of cells, with PKD2 the most abundant isotype in T lymphocytes. 25, 26 PKD have two DAG-binding domains (C1a and C1b) at the N terminus, 21 which mediate PKD recruitment to cell membranes. Protein kinase C (PKC) phosphorylation at the PKD activation loop further promotes PKD autophosphorylation and activation. 27 Based on our previous studies showing DGKα regulation of DAG in MVB formation and exosome secretion, 9, 14, 28 and the identification of PKD1/2 association to MVB, 14 we hypothesized that DGKα control of DAG mediates these events, at least in part, through PKD. Here we explored whether, in addition to its role in vesicle fission from TGN, 19 PKD regulates other steps in the DAG-controlled secretory traffic pathway. Using PKD-deficient cell models, we analyzed the role of PKD1/2 in MVB formation and function, and demonstrate their implication in exosome secretory traffic.
Results
Pharmacological PKC inhibition limits exosome secretion in T lymphocytes. DGKα limits exosome secretion in T lymphocytes. 9, 14, 28 This negative effect correlates with exosome secretion induced by addition of the cell-permeable DAG analog dioctanoyl glycerol. 14 We first assessed the role of PKD in exosome secretion by inhibiting its upstream activator PKC. RO318220 is a broad range PKC inhibitor that prevents TCR-induced and phorbol myristate acetate (PMA)-induced PKD phosphorylation by PKC.
29 RO318220 treatment inhibited PMA-induced, PKCdependent phosphorylation of endogenous PKD1/2 and of PKD1 fused to GFP (GFP-PKD1) at the activation loop (pS744/S748) 30 (Supplementary Figure S1A) ; the effect was similar for a PKD1 kinase-deficient mutant (D733A; GFP-PKD1KD). 19, 31 Inhibitor treatment also impaired PKD autophosphorylation (pS916) 27, 29 induced by carbachol (CCh) (Supplementary Figure S1B) or by anti-TCR (data not shown). We pretreated J-HM1-2.2 cells with RO318220, followed by anti-TCR or CCh stimulation to induce exosome secretion. 14 Exosomes isolated from culture supernatants 14, [32] [33] [34] were quantitated by WB using anti-CD63 or by NANOSIGHT, with similar results (Supplementary Figure S2) . RO318220-pretreated J-HM1-2.2 cells showed a notable decrease in exosomal CD63 and Fas ligand (FasL; Figures 1a and b) after stimulation with anti-TCR or CCh. These results suggest that reducing PKC-dependent, PKD activation by RO318220 treatment results in less CD63 and FasL secretion into exosomes with a comparable decrease in the number of exosomes secreted (particles/ml culture supernatant; Figure 1c ). PKD1/2 regulate exosome secretion in T lymphocytes. Although PKC inhibition can have many effects, our observations are compatible with PKD involvement in exosome biogenesis/secretion. To directly analyze PKD contribution, we used an exosome reporter secretion assay 9,14 based on transient expression of the exosome reporter DsRed2-CD63 and several GFP-PKD1 constructs, including GFP-PKD1, GFP-PKD1KD and a GFP-PKD1 version with phospho-mimetic glutamic residues that replace the PKC phosphorylation sites at S744/748 (GFP-PKD1CA). We analyzed exosome secretion by WB with anti-CD63 (Figure 2a, top) . We normalized the results to the transfection efficiency of the exosome reporter and the number of viable exosome-secreting cells (Figure 2a, bottom) .
CCh stimulation induced exosome secretion; this effect was increased by pretreatment with the DGKα inhibitor R59949.
9,14 GFP-PKD1WT expression did not markedly alter CCh-induced exosome secretion, whereas the GFP-PKD1KD mutant, which acts as a PKD1 dominant-inhibitory mutant, 19 impaired exosome secretion even in the presence of the inhibitor (Figure 2b) . These experiments support an endogenous PKD contribution to exosome secretion, although the lack of effect because of GFP-PDK1WT expression also suggests that DAG generation, directly or through PKCdependent phosphorylation, is a limiting factor in PKD activation. To test this, we used the GFP-PKD1CA mutant that bypasses the PKC phosphorylation requirement, but not that for PLC-generated DAG.
19,31 GFP-PKD1CA-expressing cells showed enhanced exosome secretion in response to CCh stimulation compared with GFP-PKD1WT-expressing cells (Figure 2b ), confirming the relevance of PKD phosphorylation by PKC for exosome secretion. Treatment with the DGKα inhibitor further increased exosome secretion by GFP-PKD1CA-expressing cells, which suggests that DGKα consumption of DAG controls PKD activation, not only through PKC-mediated phosphorylation, but also through direct DAG binding.
We compared exosome secretion by the J-HM1-2.2 cells with that of primary T lymphocytes, using various stimuli (CCh and anti-TCR for J-HM1-2.2 cells; anti-TCR for T lymphoblasts and peripheral blood lymphocytes, PBLs) (Figure 2c ). : quantification of WB signal shown in a (mean arbitrary units; AUs) in parallel with NANOSIGHT data (mean particles/ml) for the same samples. Bottom, mean x-fold induction data are shown for CD63 in exosomes (WB) and exosome concentration (NANOSIGHT). S.D. was o5% of the mean in all cases; * not significant (NS); **P ≤ 0.05 T lymphoblasts and J-HM1-2.2 cells secreted comparable exosome numbers after TCR triggering, whereas exosome secretion by PBL was not enhanced following stimulation. DGKα inhibition enhanced exosome secretion in stimulated J-HM1-2.2 cells and T lymphoblasts (Figure 2c ).
To evaluate the PKD1 effect on polarized exosome secretion in an IS model, we challenged GFP-CD63-expressing Jurkat cells with Staphylococcus enterotoxin E (SEE)-presenting Raji B cells, 35 which allowed analysis of GFP-CD63 + MVB traffic and exosome secretion. 2 cells were co-transfected with DsRed2-CD63 and the constructs GFP-PKD1WT, GFP-PKD1KD (kinase-dead) or GFP-PKD1CA (constitutively active). Cells were preincubated alone or with R59949 (R59, 10 μM) and stimulated with CCh (500 μM) to induce exosome secretion. Top, WB of exosome protein extracts developed with anti-CD63. For simplicity, R59949 alone was not included in these experiments; the inhibitor alone had no detectable effect on exosome secretion. 9, 14 Bottom, lysates of exosome-secreting cells were developed with anti-β-actin and -CD63 for normalization. (b) Quantitation of results from three experiments similar to that in a. Exosome secretion by cells expressing the distinct constructs is expressed as x-fold induction (mean ± S.D.) of three experiments, normalized to cell DsRed2-CD63 levels. (c) DsRed2-CD63-transfected J-HM1-2.2 cells, human T lymphoblasts or human PBL, alone or R59949-treated, were stimulated as indicated to induce exosome secretion. Normalized x-fold induction of exosome secretion was determined by WB analyses of DsRed2-CD63 and endogenous CD63 (eCD63). Inset, mean exosome concentration (particles/ml) secreted by the distinct cell types was determined by NANOSIGHT analyses; mean x-fold induction of exosome secretion is shown in brackets. S.D. was o5% of the mean in all cases; *not significant (NS); **P ≤ 0.05 compared with an irrelevant control (GFP). PKD thus appears to be involved in activation-induced exosome secretion in T lymphocytes in polarized and non-polarized secretion models.
PKD1 regulates exosome secretion in a B-cell model. B-cell receptor stimulation with anti-IgM activates PKD1 and PKD3 (ref. 36) and induces secretion of CD63 + exosomes, which participate in antigen presentation. [37] [38] [39] [40] To extend results from T lymphocytes, we studied exosome secretion in DT40 chicken B lymphocytes that lacked their two PKD isotypes, PKD1 and PKD3. 36 Wild-type and PKD1
DT40 cells were transfected with GFP-CD63 and exosome secretion was assessed after stimulation with PMA plus ionomycin or with anti-IgM. PMA plus ionomycin induced exosome secretion in WT, but not in PKD1 PKD2 regulates exosome secretion in primary T lymphocytes. PKD2 is the main PKD isotype in human and mouse T lymphocytes. 25, 26 We therefore analyzed T lymphoblasts from mice that lacked PKD2 (ref. 26 ) to determine its contribution to MVB traffic and exosome secretion. T lymphoblasts from WT and PKD2 − / − mice were retrovirally transduced to express GFP-CD63, and then stimulated for 18 h with plate-bound anti-TCR to induce secretory traffic of MVB. Live-cell imaging of transduced WT T lymphoblasts showed numerous GFP-CD63 + vesicles with apparently random movement within the cell, as well as weak cell surface fluorescence that may reflect constitutive CD63 traffic 42 ( Supplementary Video 3) . Following TCR stimulation, we consistently observed increased fluorescence at the plasma membrane, a finding compatible with GFP-CD63 + MVB degranulation 43, 44 (Supplementary Video 4). After stimulation, some of these vesicles approached and apparently docked to the plasma membrane. Fluorescence at the docking point increased transiently and was later lost (Supplementary Video 5, trajectories 1 and 2; Supplementary Figure S4 ), suggesting TCR-induced MVB fusion to the plasma membrane.
The increase in cell surface GFP-CD63 after TCR stimulation was probably due to GFP-CD63 transfer from the MVB limiting membrane to the plasma membrane (Supplementary Video 5, Figure 5a ). The ratio of plasma membrane to total GFP-CD63 fluorescence intensity after TCR stimulation increased similarly in PKD2
− / − and WT T lymphoblasts (Figure 5a ). After TCR stimulation, the mean velocity of CD63 + MVB was also similar in PKD2 − / − and WT T lymphoblasts (data not shown). In contrast, WB analysis showed lack of inducible exosome secretion in PKD2 − / − T lymphoblasts (Figure 5b) . Lack of PKD2, therefore, did not alter TCR-induced MVB docking and fusion nor MVB velocity, but limited exosome secretion. PKD2 reconstitution of PKD2 − / − T lymphoblasts enhanced TCR-triggered exosome secretion compared with PKD2
− / − or WT T lymphoblasts (Figure 5c ). (Figures 5a,6b,Supplementary Video 6 ). These data demonstrate that PKD regulates exosome secretion, at least in part through control of MVB morphogenesis.
DGKα regulates PKD1/2 activation. PKD positively controls MVB maturation and exosome secretion, whereas DGKα enzyme activity negatively regulates these processes, 9 and the DGKα inhibitor did not rescue GFP-PKD1KD mutant inhibition of exosome secretion (Figure 2b ). DGKα may thus control PKD1 activation in a pathway that governs MVB maturation and exosome secretion. We analyzed this using J-HM1-2.2 cells alone or treated with the DGKα inhibitor R59949, and activated with CCh, anti-TCR or anti-TCR plus anti-CD28. WB analysis of R59949-treated cells showed an increase in active PKD1/2, as measured by phosphorylation on S744/S748. This increase was most evident from 30 min to 3-h post-stimulation (Figure 7a ). R59949 treatment did not enhance PMAinduced PKD1/2 phosphorylation (data not shown), indicating that the effect was specific for the TCR and HM1R, which activate PKD1/2 via PLC-generated DAG.
To test whether DGKα overexpression affects PKD1/2 activation, we transfected J-HM1-2.2 cells with DsRe d2-PKD1 alone or co-transfected with GFP-DGKα, and stimulated them with CCh or PMA plus ionomycin (which induces DAG-independent PKD1/2 activation). WB analysis with anti-(pS744/748)PKD1/2 showed less DsRed2-PKD1 and endogenous PKD1/2 phosphorylation in CCh-treated, GFP-DGKα and DsRed2-PKD1 co-expressing cells than in cells that expressed DsRed2-PKD1 alone. This phosphorylation difference was not observed in PMA plus ionomycin-stimulated cells (Figure 7b) .
We tested the effect of attenuating DGKα expression on PKD activation in the IS model. Jurkat cells stimulated with PMA or SEE-pulsed Raji cells to induce synapse formation showed an increase in (pS916)PKD1/2 signal, which colocalized with CD63 (PMA) or synaptic membrane (SEE-pulsed Figure S3 ) were transfected with GFP-CD63 and stimulated for the indicated times with PMA (10 ng/ml) plus ionomycin (0.5 μg/ml) (a) or anti-IgM (10 μg/ml) (b). We analyzed GFP-CD63 in cell lysates and exosomes using WB and quantified the x-fold induction (mean ± S.D.) of exosome secretion of GFP-CD63, normalized to cell GFP-CD63 levels (c). Statistical significance corresponds to exosome secretion at the same time points of WT versus PKD1
− / − DT40 cells were stimulated with anti-IgM, exosomes isolated and endogenous CD63 (eCD63) analyzed in cell lysates and exosomes using WB; quantification is shown in e, normalized to cellular eCD63. Statistical significance corresponds to exosome secretion at the same time points of WT versus PKD1 − / − DT40 cells. Figure S5) . DAG consumption by DGKα thus limits PKD1/2 recruitment to and activation at the IS.
PKD2 controls CTL activity and AICD in T lymphoblasts.
Cytotoxic T lymphocytes (CTLs) cytotoxic granules have a MVB structure and contain perforin, granzymes and FasL; 44 ILVs from these MVBs are released to the synaptic cleft as exosomes. 10 MVB degranulation and FasL secretion on exosomes mediates AICD of CD4 + T lymphocytes and Jurkat cells.
14, 33 We next examined the effect of PKD2 deficiency on CTL activity and AICD. We used a murine IS model in which TCR-stimulated T lymphoblasts were challenged with Staphylococcus enterotoxin B (SEB)-pulsed, CMAC-labeled EL-4 cells. SEB binds to Vβ3,7,8,17-TCR-bearing T cells, which in mice make up a large proportion (~30%) of T lymphocytes, 50 and induces T-cell activation and AICD. 
CTL activity was lower in PKD2
− / − than in WT T lymphoblasts, with a concomitant decrease in AICD (Figure 9, top) . As only 30% of mouse T lymphoblasts express the SEBresponsive Vβ TCR, we restimulated T lymphoblasts with polyclonal anti-TCR with similar results (Figure 9 , bottom). The lack of PKD2 thus reduced both AICD and CTL activity in primary T lymphoblasts.
Discussion
Exosomes are constitutively secreted by a variety of cell lineages and tumor cells, but T and B lymphocytes show inducible exosome secretion upon TCR and BCR triggering. 54, 55 IS formation leads to polarization and membrane fusion of MVB, which release ILV as FasL-containing exosomes that trigger Fas-dependent AICD, 13 ,33 maintaining T lymphoid homeostasis. 56, 57 CTL degranulation leads to specific, TCR-controlled target cell apoptosis. 55 MVB biogenesis and secretion are thus important for immune effector responses and T-cell homeostasis.
DGKα acts as negative regulator of MVB maturation and exosome secretion by T lymphocytes. 9, 14 Here we identify PKD as the major DAG effector that regulates MVB maturation and exosome secretion in T and B lymphocytes. Using pharmacological inhibition, DGKα overexpression and siRNA-mediated DGKα silencing, we show that DGKα controls MVB-mediated secretory traffic at least in part by limiting PKD activation. DGKα inhibition enhances exosome secretion in cells that express a PKD1 mutant that bypasses PKC activation requirements (GFP-PKD1CA); this suggests that in addition to limiting PKD phosphorylation by PKC, DGKα controls direct PKD activation by DAG.
This negative DGKα role contrasts with its positive function in MVB polarization to the IS. 9 The molecular basis of this dual DGKα contribution to MVB formation and polarization is not fully understood, but may be linked to its ability to transform DAG into PA. Recent studies showed that DGKα controls late endosome polarized traffic in various cell lineages. DGKα-deficient CTL show defects in formation of the DAG gradient at the IS, as well as microtubule-organizing center (MTOC) reorientation. 58 In breast carcinoma cells, DGKα-mediated PA generation mediates integrin recycling at the tips of invasive pseudopodial structures during invasive migration. 59 Additional studies are needed to determine whether DGKα-generated PA and/or its DAG consumption are necessary for MVB polarization to the IS.
The PKD effectors that contribute to regulation of MVB maturation are not known. The aberrant CD63 + endosome phenotype in PKD-deficient B and T cells resembles that was observed after PI3K inhibition (Figure 6a ). This suggests a role for PKD upstream of PI3K and correlates with studies that identified PKD phosphorylation and activation of class III PI3K Vps34. 60 PI3P is a master organizer of endosomal sorting, and promotes recruitment of several proteins that regulate various steps in trafficking, including endosomal fusion and ESCRT-dependent intraluminal sorting of cargoes.
61 J-HM1-2.2 cells that express an ATPase-deficient mutant VPS4 (ref. 9) have aberrant endosomes similar to those seen in DT40 cells − / − T lymphoblasts stimulated with plate-bound anti-TCR (2C11, 10 μg/ml). Statistical significance corresponds to percentage of apoptosis of EL-4 and T lymphocytes at the same effector to target/stimulator cell ratio of WT versus PKD2 KO T lymphoblasts. *not significant (NS), **P ≤ 0.05 PKD1/2 regulates exosome secretion C Mazzeo et al after PI3K inhibition. The comparable anomalous shape of CD63 + vesicles as a result of PKD2 deficiency provides a molecular mechanism for DGKα-negative contribution to MVB maturation and suggests that PKD2 acts as a DAG sensor that also modulates membrane PI3P levels.
PKD2 is the major PKD isotype expressed in human and mouse T lymphocytes. 25, 26 In Jurkat T cells, GFP-tagged PKD1 and endogenous PKD2 have identical regulatory mechanisms, as well as similar activation kinetics and subcellular localization in response to TCR. 62 The effects observed for exogenously expressed PKD1 constructs may thus be the result of inhibition of endogenous PKD2 and activation of PKD2 downstream effectors. The PKD2
− / − mouse model confirms the contribution of this isoform to exosome secretion, and extends findings from DT40 B and Jurkat T cells to primary T lymphocytes. In response to TCR triggering, PKD2
− / − T lymphoblasts show severe inhibition of IL-2 secretion, 26 although TCR-induced IL-2 gene expression was unaffected. 63 Defective IL-2 secretion by PKD2 − / − T cells and the impaired exosome secretion we describe here could indicate a general secretion defect because of loss of PKD2. Indeed, a recent phosphoproteomic study of PKD2 − / − CTL identified several traffic-related proteins as PKD2 substrates. 64 Our data characterize a role for PKD2 in primary T-cell AICD and coincide with studies showing that expression of a constitutively active PKD2 mutant in Jurkat cells enhances AICD. 25 Although loss of PKD2 enhances thymic output during T lymphocyte development, it does not affect T-cell selection or inhibit expression of Vβ8 TCR, 63 the major murine TCR repertoire recognized by SEB.
50 PKD2 − / − T lymphoblasts show no changes in TCR-triggered, transcriptional induction of genes that encode proteins involved in CTL activity and AICD, such as FasL and perforin. 55, 63 It remains to be determined whether the splenomegaly and lymphadenopathy in TCR transgenic PKD2 − / − mice are due exclusively to enhanced thymic output 63 or whether there is a contribution by an AICD defect. The decrease in CTL activity of PKD2 − / − versus WT T lymphoblast-containing mixed cultures is underestimated, as PKD2 − / − T lymphocytes undergo less AICD than WT T lymphoblasts (Figure 9 ), leading to an increase in the number of effector PKD2 − / − T lymphoblasts. This reinforces the role of PKD2 as an important regulator of CTL activity.
Several studies have established an essential role for PKD and its activator DAG in Golgi-dependent secretory function. DAG-mediated PKD activation regulates vesicle budding and fission from the TGN, a process negatively regulated by DGK. 16, 19, 65 Our results here identify an additional PKD1/2 function as a major downstream effector of DGKα in the control of MVB traffic and exosome secretion in T and B cells. DGKα-mediated DAG consumption limits PKD subcellular location and activation in T ymphocytes during IS formation. PKD1/2 is necessary for MVB maturation and exosome secretion in T and some B cells, and thus contributes to crucial lymphocyte immune functions such as cytotoxic activity and AICD.
Materials and Methods
Cells and mice. J-HM1-2.2 Jurkat cells expressing HM1R 66 were stimulated with CCh (Sigma, St. Louis, MO, USA; final concentration 500 μM) 67 or plate-bound anti-CD3 antibody (10 μg/ml, UCHT1; BD Biosciences, San Jose, CA, USA), or PMA (10 ng/ml) plus ionomycin (0.5 μg/ml). We used the DGK inhibitor II R59949 (10 μM; Calbiochem, Merck KGaA, Darmstadt, Germany), the PKC inhibitor RO318220 (0.5 μM; Roche, F. Hoffmann-La Roche AG, Basel, Switzerland) and the PI3K inhibitor LY294002 (10 μM; Promega, Madison, WI, USA). The human Raji B-cell and the EL-4 mouse T-cell lines (ATCC, Manassas, VA, USA) were used for IS experiments. Generation, culture and activation of PKD1 Expression vectors, transfection assays and retroviral transduction. pEFbos-GFP and pEFGFP-DGKα have been described; 14, 23 pEFGFP-C1-CD63 and pECFP-C1-CD63 were a generous gift from Dr. G Griffiths; 68 pEFGFPPKD1wt, pEFGFP-PKD1-D733A and pEFGFP-PKD1-S744E/S748E have been described. 27 pDsRed2-CD63 and pDsRed2-PKD1wt were prepared by subcloning cDNA for human CD63 from pEFGFP-C1-CD63, or PKD1wt from pEFGFP-C1-PKD1wt, into the pDsRed2-C1 vector (BD Biosciences). Constructs were verified by sequencing. Expression vectors for GFP-VPS4 wt and GFP-VPS4EQ mutant were a gift of Dr. P Whitley. 69 For transfection experiments, J-HM1-2.2 or DT40 cells were transiently transfected with 20-30 μg of plasmids as described, 70 DGKα was silenced using the pSUPER RNAi System (pSR-GFP bicistronic or pSuper plasmids; Oligoengine, Seattle, WA, USA) with the appropriate hairpin. 9 The retroviral vector pBMN-Z (Addgene, Cambridge, MA, USA) was HindIII-and NotI digested to remove LacZ; a 0.7-kb insert bearing EGFP (NCBI AAB02574.1) was excised from EGFP-N1 (Clontech, Mountain View, CA, USA) using HindIII and NotI and inserted into pBMN in place of LacZ (pBMN-GFP). PKD2wt cDNA was excised from pCR-Blunt II-TOPO-PKD2WT using HindIII and NotI and inserted into the digested pBMN vector (pBMN-GFP-PKD2). Human CD63 was excised from pCRBlunt-EFGFP-CD63 using NotI and inserted into digested pBMN vector to yield pBMN-GFP-hCD63. Constructs were verified by sequencing. Phoenix ecotropic packaging cells (Stanford University) were transfected with 5-10 μg plasmid (pBMN-GFP, pBMN-GFP-CD63 and pBMN-GFP-PKD2wt) using a standard calciumphosphate transfection protocol. At~12-18 h post-transfection, medium was renewed. After 24 h (37ºC, 5% CO 2 ), retroviral supernatants were centrifuged briefly (500xg, 5 min) to remove packaging cells and viral particles concentrated by highspeed centrifugation (20 000xg, 4 h, 4ºC). Supernatants were discarded and concentrated viral particles resuspended in 1 ml medium, snap-frozen and stored at -80ºC. Primary spleen T cells (10 6 cells per well) were mixed with freshly thawed retrovirus supernatant (1 ml) and polybrene (Sigma; 10 μg/ml). Plates were centrifuged (650xg, 60 min), 1 ml per well IL-2-containing medium (20 ng/ml) was added and cells were incubated (24 h), then centrifuged to remove polybrene, resuspended in fresh medium with IL-2 and incubated as before. Infection efficiency was assessed at 48 h using epifluorescence microscopy to detect GFP + cells. We infected PKD2
− / − T lymphoblasts with helper-free ecotropic and amphotropic retrovirus stock (with pBMN-EGFP-CD63) to obtain GFP-CD63-expressing cells; for GFP-PKD2 reconstitution experiments, we infected PKD2 − / − T lymphoblasts with a mixed retrovirus stock (pBMN-EGFP-CD63 and pBMN-GFP-PKD2).
Isolation and quantitation of exosomes. Exosomes were isolated from culture supernatants as described. [32] [33] [34] There were no differences in β-actin levels in cell lysates, which indicates that the exosomes were produced by equal numbers of viable cells. Using standard protocols, supernatants of 20 × 10 6 cells were centrifuged sequentially at low speed, clarified 71 and exosomes recovered by ultracentrifugation (100 000xg, 12 h, 4ºC) . 33 In experiments to quantify exosomes and analyze their size distribution, the final culture supernatant collected before ultracentrifugation was diluted (1/5) in HBSS and analyzed using NANOSIGHT (calibrated with 100 and 400 nm fluorescent calibration beads; Malvern, Malvern, UK). We analyzed exosomes from cells expressing the exosome reporters GFP-CD63 and DsRed2-CD63 in a similar protocol, using 10 6 J-HM1-2.2 cells or 4 × 10 6 DT40 cells. To measure endogenous CD63 in exosomes, we normalized WB signals for exosome-producing cell number to those for β-actin or endogenous CD63. To analyze GFP-CD63 or DsRed2-CD63 reporters in exosomes, we normalized WB signals for exosome CD63 to those in cell lysates for each condition tested. CD63 is found in MVB, ILV and hence in exosomes; this protein and its chimeras (GFP-CD63) are used as reporters for MVB/exosomes, 2, 8, 14 and allow quantitation of exosome secretion. 9, 71 Western blot analysis of endogenous or chimeric CD63 in isolated exosomes is used to measure exosomes, 9 as the signal correlates with nanoparticle concentration data (nanoparticles/ml) as confirmed by Nanopaticle Tracking Analysis (NTA) 72, 73 (Supplementary Figure S2) . In preliminary experiments, we probed WB of purified exosomes with another exosome marker (Lamp-1) and plasma membrane markers (CD45 and CD28), to exclude the presence of cell debris, apoptotic bodies and/or shedding vesicles (Supplementary Figure S2) . For murine T lymphoblasts, culture supernatants of 18 × 10 6 uninfected cells were concentrated (Amicon Ultra; Millipore, Merck KGaA, Darmstadt, Germany,) and centrifuged sequentially. Exosomes were obtained from 2 × 10 6 spleen T lymphoblasts expressing the exosome reporter GFP-CD63.
Preparation of whole-cell and exosome lysates and western blot analysis. Exosomes were resuspended in 60 μl RIPA lysis buffer and 20 μl of this lysate were analyzed by WB. We generally obtained 50-150 μg protein in the pellet from 20 × 10 6 stimulated cells. For WB, each lane contained the total exosomal protein recovered from medium for the same number of untreated or stimulated cells. Cells and exosomes were lysed (10 min) in RIPA buffer with protease inhibitors, proteins separated in reducing SDS-PAGE and transferred to Hybond ECL membranes (GE Healthcare, Wauwatosa, WI, USA). For CD63 detection, proteins were separated in non-reducing conditions. 74 Blots were incubated with rabbit anti-pPKD or mouse anti-CD63 and developed with appropriate HRP-conjugated secondary antibodies using ECL reagents following standard protocols. Data were quantitated using Quantity One 4.4.0 software (Bio-Rad, Hercules, CA, USA).
Immunofluorescence. Living cells expressing GFP-CD63 were attached to fibronectin-coated glass-bottom 35 mm culture dishes (Mat-Tek, Ashland, MA, USA) at 24-48 h post-transfection, and stimulated in medium without phenol red (37 ºC).
70
ISs between transfected Jurkat cells and SEE-pulsed (1 μg/ml), CMAC-labeled Raji cells were analyzed as described. 9 In mouse cell IS experiments, CMAC-labeled EL-4 cells were SEB-pulsed (1 μg/ml) and challenged with T lymphoblasts from WT mice at a 1 : 1 ratio. For time-lapse video experiments, we using an OKO-lab stage incubator on a Nikon Eclipse TiE microscope with a DS-Qi1MC digital camera and a Plan Apo VC 60x NA 1.4 objective. For video acquisition and analysis, we used NIS-AR software (Nikon, Tokyo, Japan). Epifluorescence images were deconvoluted with Huygens Deconvolution Software (Scientific Volume Image, Hilversum, Holland). Digital images were quantified with NIS-AR or ImageJ software (Rasband, WS, ImageJ, US National Institutes of Health, http://rsb.info.nih.gov/ij/). Video images of GFP-CD63 vesicle trajectories were plotted and analyzed with NIS-AR and ImageJ MJTrack plugin. Significance of results for single cells was determined using ANOVA to analyze at least 20 cells from different fields for at least three experiments per condition.
CTL and AICD assays. For CTL and AICD assays, EL-4 cells were SEBpulsed (1 μg/ml) and challenged with WT and PKD2 − / − mouse T lymphoblasts at various effector/target ratios in U-bottom 96-well culture plates (5 h), then annexin V-PE stained to analyze the percentage of apoptotic cells by flow cytometry. Forward and side scatter detectors were calibrated to optimize discrimination of the cell populations, to gate EL-4 and T lymphoblasts by size and complexity, and simultaneously measure percentage of apoptosis of EL-4 (CTL activity) and T lymphoblasts (AICD).
